BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27235684)

  • 21. Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing.
    Saeed M; Xu Z; De Geest BG; Xu H; Yu H
    Bioconjug Chem; 2020 Feb; 31(2):404-415. PubMed ID: 31951380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor reactive T cells get a boost.
    Pardoll DM
    Nat Biotechnol; 2002 Dec; 20(12):1207-8. PubMed ID: 12454671
    [No Abstract]   [Full Text] [Related]  

  • 24. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene.
    Doubrovin MM; Doubrovina ES; Zanzonico P; Sadelain M; Larson SM; O'Reilly RJ
    Cancer Res; 2007 Dec; 67(24):11959-69. PubMed ID: 18089827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo tracking of Th1 cells by PET reveals quantitative and temporal distribution and specific homing in lymphatic tissue.
    Griessinger CM; Kehlbach R; Bukala D; Wiehr S; Bantleon R; Cay F; Schmid A; Braumüller H; Fehrenbacher B; Schaller M; Eichner M; Sutcliffe JL; Ehrlichmann W; Eibl O; Reischl G; Cherry SR; Röcken M; Pichler BJ; Kneilling M
    J Nucl Med; 2014 Feb; 55(2):301-7. PubMed ID: 24434289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 27. Dual-specific T cells combine proliferation and antitumor activity.
    Kershaw MH; Westwood JA; Hwu P
    Nat Biotechnol; 2002 Dec; 20(12):1221-7. PubMed ID: 12415288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular immunotherapy of cancer: an overview and future directions.
    Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
    Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immuno-PET Imaging of Engineered Human T Cells in Tumors.
    Mall S; Yusufi N; Wagner R; Klar R; Bianchi H; Steiger K; Straub M; Audehm S; Laitinen I; Aichler M; Peschel C; Ziegler S; Mustafa M; Schwaiger M; D'Alessandria C; Krackhardt AM
    Cancer Res; 2016 Jul; 76(14):4113-23. PubMed ID: 27354381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.
    Chicaybam L; Bonamino MH
    Int Rev Immunol; 2014 Oct; 33(5):402-16. PubMed ID: 24911925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptively transferred anti-CD3-activated T cells for human tumor immunotherapy.
    Gold JE
    J Clin Oncol; 1993 Sep; 11(9):1836-7. PubMed ID: 8355052
    [No Abstract]   [Full Text] [Related]  

  • 34. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative imaging of the T cell antitumor response by positron-emission tomography.
    Dubey P; Su H; Adonai N; Du S; Rosato A; Braun J; Gambhir SS; Witte ON
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1232-7. PubMed ID: 12547911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells.
    Li J; Theofanous L; Stickel S; Bouton-Verville H; Burgin KE; Jakubchak S; Wagner TE; Wei Y
    Int J Oncol; 2007 Jul; 31(1):193-7. PubMed ID: 17549421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET imaging of the immune system: immune monitoring at the whole body level.
    Singh AS; Radu CG; Ribas A
    Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):281-90. PubMed ID: 20639814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
    Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
    Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
    Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.